XML 50 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Disclosures - Schedule of Selected Financial Information with Respect to Single Operating Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 52 $ 529
Research and development    
Total research and development 27,467 17,210
General and administrative 14,789 5,788
Total operating expenses 42,256 22,998
Loss from operations (42,204) (22,469)
Other income, net 5 (9)
Net loss and comprehensive loss (34,452) (16,934)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Revenue 52 529
Research and development    
Clinical and manufacturing 23,065 14,226
Other research and development 4,402 2,984
Total research and development 27,467 17,210
General and administrative 14,789 5,788
Total operating expenses 42,256 22,998
Loss from operations (42,204) (22,469)
Other income, net 7,752 5,535
Net loss and comprehensive loss $ (34,452) $ (16,934)